These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 34727316)

  • 1. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
    Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
    Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
    Chase DM; Annavarapu S; Tseng WY; Shi J; Szamreta E; Monberg M
    Gynecol Oncol; 2024 Jan; 180():79-85. PubMed ID: 38056115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study.
    Han GH; Kim HR; Yun H; Kim JH; Cho H
    Target Oncol; 2024 Mar; 19(2):251-262. PubMed ID: 38416378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
    Guy H; Walder L; Fisher M
    Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
    Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis.
    Luo J; Ou S; Wei H; Qin X; Jiang Q
    Front Oncol; 2022; 12():815265. PubMed ID: 35756600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States.
    Murayama A; Marshall DC
    Gynecol Oncol; 2024 Feb; 181():83-90. PubMed ID: 38147713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Wu L; Zhong L
    J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
    Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
    Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients.
    Lee CS; Hernandez J; Liang C; Leung A; Stefanov DG; Cheng K; John V
    J Pharm Pract; 2023 Oct; 36(5):1134-1141. PubMed ID: 35439094
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review.
    Borrelli EP; McGladrigan CG
    J Oncol Pharm Pract; 2020 Dec; 26(8):1977-1986. PubMed ID: 32659172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibitors in Ovarian Cancer: A Review.
    O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
    Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting.
    Rimel BJ; Chase DM; Perhanidis J; Ghazarian AA; Du EX; Wang T; Song J; Golembesky AK; Hurteau JA; Kalilani L; Salani R; Monk BJ
    Gynecol Oncol Rep; 2024 Feb; 51():101332. PubMed ID: 38362364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
    Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
    Zhou S; Jiang Y; Luo C; Yuan L
    Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system.
    Hatch RV; Patel SU; Cambareri C; Uritsky T; Martin LP
    J Oncol Pharm Pract; 2022 Jul; 28(5):1102-1110. PubMed ID: 34134553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
    Madariaga A; Bowering V; Ahrari S; Oza AM; Lheureux S
    Int J Gynecol Cancer; 2020 Jul; 30(7):903-915. PubMed ID: 32276934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
    Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK
    J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.